152 curative gastrectomy specimens from the patients with gastric carcinoma were examined in an attempt to assess the prognostic value of c-erbB-2 and mutant p53 protein expressions. The labeled streptavidin-biotin method was applhed to routinely
fixed
and paraffin-embeddedtissue sections, using the polyclonal and monoclonal antibodies against the c-erbB-2 protein and the mutant or p53 protein, respectively. In this examination, staining of c-erbB-2 protein was foun in 9.2% of these carcinomas.
The
c-erbB-2 stained tumors were significantly associated with the tumors whose diameters were smaller than 5 cm, and more likely to be associated with serosal invasion and nodal involvement than the unstained ones. However, there was little
association
between staining of c-erbB-2 protein and clinicaopathologic findings such as age, sex, location, histology, gross type, lymph node statis, depth of invasion, and stage. The survival analysis of 104 patients with stage III gastric carcinoma
revcaled
no
significant association between c-erbB-2 staining status and survival duration. The 5-year survival rates of the c-erbB-2 positive group and its negative group were 21% and 28%, respectively Positive p53 protein expression was observed in 46% of
152
carcinomas. There was no significant association between p53 expression and parameters such as age, sex, location, histology, gross type, and size. The p53 stained tumors were more likely to be associated with lymph node metastasis, serosal
invasion
than p53 unstained ones; but this did not reach significance. The 5-year survival retes of the p53 positive group and counter part group were 27% and 31%, respectively. Although the difference among 5-year survival rates was not significant. it
was
noticeable that 5-year survival rate was relatively low in the group of patients with positive p53 protein expression, whose tumor was smaller than 5 cm in diameter. It is believed that there was a higher incidence of lymph node metastasis when
p53
protein expression occurred in the tumors smaller than 5 cm in diameter. It suggests that p53 protein has a possible role in lymph node metastasis. When the status of c-erbB-2 and p53 protein tissue expression and clinicopathologic factors
(including
such known prognostic factors as lymph node status and depth of invasion) were simultaneously analyzed by means of multiple linear regression, the results of our study showed that the expressions of product of c-erbB-2 oncogene or p53 tumor
supressor
gene had little prognostic significance in gastric carcinoma.
|